Comerica Bank Buys 550,000 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

Comerica Bank boosted its position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 220.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 800,000 shares of the company's stock after purchasing an additional 550,000 shares during the period. Comerica Bank owned about 0.36% of Lineage Cell Therapeutics worth $402,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Defender Capital LLC. boosted its position in Lineage Cell Therapeutics by 19.2% in the fourth quarter. Defender Capital LLC. now owns 5,963,348 shares of the company's stock worth $2,997,000 after purchasing an additional 961,150 shares during the last quarter. Barclays PLC boosted its position in Lineage Cell Therapeutics by 311.3% in the third quarter. Barclays PLC now owns 211,300 shares of the company's stock worth $192,000 after purchasing an additional 159,924 shares during the last quarter. Atria Wealth Solutions Inc. purchased a new position in Lineage Cell Therapeutics in the fourth quarter worth about $29,000. SG Americas Securities LLC boosted its position in Lineage Cell Therapeutics by 35.5% in the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company's stock worth $35,000 after purchasing an additional 18,053 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Lineage Cell Therapeutics by 1,058.3% in the fourth quarter. Renaissance Technologies LLC now owns 2,283,072 shares of the company's stock worth $1,147,000 after purchasing an additional 2,085,972 shares during the last quarter. 62.47% of the stock is owned by hedge funds and other institutional investors.

Lineage Cell Therapeutics Stock Up 1.3%

LCTX traded up $0.01 during trading hours on Wednesday, reaching $0.49. 52,444 shares of the company's stock traded hands, compared to its average volume of 1,298,731. The firm has a 50-day moving average price of $0.46 and a 200 day moving average price of $0.63. Lineage Cell Therapeutics, Inc. has a 52-week low of $0.37 and a 52-week high of $1.15. The firm has a market capitalization of $108.45 million, a PE ratio of -4.10 and a beta of 1.21.

Analyst Ratings Changes

Several research analysts have recently commented on LCTX shares. D. Boral Capital reaffirmed a "buy" rating and issued a $2.00 price objective on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. B. Riley decreased their target price on Lineage Cell Therapeutics from $4.00 to $3.00 and set a "buy" rating on the stock in a research note on Friday, March 14th. Finally, HC Wainwright reissued a "buy" rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Lineage Cell Therapeutics presently has an average rating of "Buy" and a consensus target price of $4.20.

Lineage Cell Therapeutics Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.